Communiqués Galectin Therapeutics Inc.

Actions

GALT

US3632252025

Recherche biotechnologique et médicale

Temps réel estimé Cboe BZX 15:46:20 05/10/2026			Varia. 5j.	Varia. 1 janv.
3,815 ^USD	-2,18 %		-1,89 %	-7,31 %

14/08	Galectin Therapeutics Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI
23/06	Galectin Therapeutics parvient à un accord avec la FDA sur le critère d’évaluation principal et la voie réglementaire à suivre pour belapectin chez des patients atteints de cirrhose liée à la MASH et d’hypertension portale	CI

Communiqués

10/09	Galectin Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference	AQ
14/08	Galectin Therapeutics : Reports June 30, 2026 Financial Results and Provides Business Update	PU
14/08	Galectin Therapeutics Reports June 30, 2026 Financial Results and Provides Business Update	AQ
04/08	Galectin Therapeutics Announces Conversion of $105.8 Million in Debt to Equity, Significantly Strengthening Balance Sheet	AQ
23/06	Galectin Therapeutics Announces Positive Type C Meeting with the FDA for Belapectin in Patients with MASH Cirrhosis and Portal Hypertension	AQ
27/05	Galectin Therapeutics Presents New EASL 2026 Oral and Poster Analyses Demonstrating Belapectin’s Potential to Modify Disease Progression in Advanced MASH Cirrhosis	AQ
15/05	Galectin Therapeutics Reports March 31, 2026 Financial Results and Provides Business Update	AQ
11/05	Galectin Therapeutics Announces Publication of NAVIGATE Phase 2b Trial Results for Belapectin in the Journal of Hepatology	AQ
28/04	Galectin Therapeutics : KOL Event Presentation, March 2026	PU
31/03	Galectin Therapeutics Reports 2025 Financial Results and Provides Business Update	AQ
17/03	Galectin Therapeutics Strengthens Board of Directors with Appointment of Henry Brem, M.D.	AQ
26/02	Galectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin Development Program for Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) Cirrhosis and Portal Hypertension, on March 10, 2026 at 12:00 PM ET	AQ
19/12	Galectin Therapeutics Provides Regulatory Update Following FDA Written Response and Announces an Additional $10 Million Line of Credit from Richard E. Uihlein Sufficient to Cover Expected Expenditures Through March 2027	AQ
05/12	Galectin Therapeutics : Corporate Presentation, December 2025	PU
14/11	Galectin Therapeutics Reports Financial Results for the quarter ended September 30, 2025, and Provides Business Update	AQ
10/11	Galectin Therapeutics : Corporate Presentation, November 2025	PU
10/11	Galectin Therapeutics Presented NAVIGATE Trial Results at the American Association for the Study of Liver Diseases (AASLD) 2025 Annual Meeting	AQ
20/10/25	Galectin Therapeutics to Present at the H.C. Wainwright 9th Annual MASH Investor Conference	AQ
07/10/25	Galectin Therapeutics to Present at the American Association for the Study of Liver Disease (AASLD) Liver Meeting 2025	AQ
08/09/25	Galectin Therapeutics : Corporate Presentation, September 2025	PU
02/09/25	Galectin Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference	AQ
19/08/25	Galectin Therapeutics : Corporate Presentation, August 2025	PU
14/08/25	Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2025 and Provides Business Update	AQ
09/07/25	Galectin Therapeutics Announces New $10 Million Credit Line from Richard E. Uihlein, Sufficient to Cover Expected Expenditures Through June 2026	AQ
16/06/25	Galectin Therapeutics : KOL Event Presentation, June 2025	PU